← Back to headlines
Cathie Wood's CRISPR Therapeutics Investment Backed by Underrated Catalyst
Cathie Wood's ARK Invest has made a significant $362 million bet on CRISPR Therapeutics, with analysts suggesting the investment is supported by a catalyst that many investors are currently underrating. This highlights a bold investment strategy in the biotech sector.
22 Jul, 09:50 — 22 Jul, 09:50
Sources
Showing 1 of 1 sources
